Credit Suisse initiated coverage on OmniAb Inc OABI with an Outperform rating and a price target of $13. The company is spun off of Ligand Pharmaceuticals Inc’s LGND antibody discovery business. The analyst says the company is the industry’s only four-species antibody discovery platform (rat, mouse, chicken, cow) with a flexible business model that can feed directly into […]